Pulmonary Vasculature

Latest News

Sotatercept Receives Breakthrough Therapy Status for Pulmonary Arterial Hypertension

The FDA has granted Breakthrough Therapy designation to sotatercept (Acceleron Pharma) for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization Group 1).

Ambrisentan and Tadalafil Combination Therapy Appropriate for CTD-PAH

Combination therapy is appropriate for patients with typical pulmonary arterial hypertension who are categorized as low and intermediate risk at baseline.

Obesity Found to Increase the Risk for Pulmonary Hypertension

Obesity may be associated with a greater risk for pulmonary hypertension.

Trulicity Approved to Reduce Risk for Major Adverse Cardiovascular Events

Remunity is indicated for continuous subcutaneous delivery of Remodulin to treat pulmonary arterial hypertension in patients ≥22 years of age.

Study Shows INOpulse Promising for Pulmonary HTN With Pulmonary Fibrosis

Bellerophon Therapeutics announced positive topline data from the phase 2b study of INOpulse® (pulsed, inhaled nitric oxide) delivery system for the treatment of pulmonary hypertension associated with pulmonary fibrosis (PH-PF).

Pulmonary Hypertension Risk Estimation Changes May Predict Mortality After Valve Replacement

Incorporating preoperative right heart measurements into the standard pulmonary hypertension risk estimation model may allow for better risk stratification following aortic valve replacement.

Anticoagulation Improves Outcomes in Idiopathic PAH, but Not CTD-PAH

Systemic anticoagulation was found to improve quality-adjusted life years among patients with idiopathic pulmonary arterial hypertension but not among those with connective tissue disease-associated pulmonary arterial hypertension.

No Causal Association Between Red Cell Distribution Width and PAH

No causal association between elevated red cell distribution width and pulmonary arterial hypertension was established.

Drug-Device Promising in PH-ILD

Bellerophon Therapeutics announced positive topline results from cohort 2 of an ongoing phase 2/3 iNO-PF study of INOpulse delivery system for the treatment of PH-ILD.

FOCUS May Be Useful for Ruling Out Pulmonary Embolism in Patients Presenting to the ED With Abnormal Vital Signs

In patients with abnormal vital signs presenting to the emergency department who are suspected of having a pulmonary embolism, a negative focused cardiac ultrasound examination may be associated with reduced odds of a pulmonary embolism diagnosis.